2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Fat Mass and Obesity-associated Protein (FTO)

Fat Mass and Obesity-associated Protein (FTO)

Fat mass and obesity-associated gene (FTO) is a member of the Fe (II)- and oxoglutarate-dependent AlkB dioxygenase family and is linked to both obesity and intellectual disability. Previous studies revealed FTO plays pivotal roles in adipogenesis and energy homeostasis. FTO-deficient mice display postnatal growth retardation and reduced food intake, with a significant reduction of adipose tissue, whereas the overexpression of FTO caused obesity in mice. In addition, the role of FTO as an RNA demethylase of N6-methyladenosine (m6A) may be related to its important roles in neurogenesis, learning and memory. FTO protein is also found to be highly abundant in brain and is associated with reduced brain volume in adolescents and older people. FTO gene deficiency enhances the retention of fear memory and also impairs dopamine receptor 2- and 3-dependent control of neuronal activity and locomotor behavioral responses.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-W026109
    FTO-IN-12
    		Inhibitor
    FTO-IN-12 (Compound 2) is an inhibitor of fat mass and obesity-related protein (FTO). Kd and IC50 values are 185 nM and 1.46 μM, respectively. FTO-IN-12 can be used in the study of neurodegenerative diseases.
    FTO-IN-12
  • HY-117275A
    Meclofenamic acid sodium hydrate
    		Inhibitor
    Meclofenamic acid (Meclofenamate) sodium hydrate is a non-steroidal anti-inflammatory agent. Meclofenamic acid sodium hydrate is a highly selective FTO (fat mass and obesity-associated) enzyme inhibitor. Meclofenamic acid sodium hydrate competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid sodium hydrate is a non-selective gap-junction blocker. Meclofenamic acid sodium hydrate inhibits hKv2.1 and hKv1.1, with IC50 values of 56.0 and 155.9 μM, respectively.
    Meclofenamic acid sodium hydrate
  • HY-170668
    DDO-02267
    		Inhibitor
    DDO-02267 is a selective and lysine-targeting covalent inhibitor of ALKBH5, with an IC50 value of 0.49 μM. DDO-02267 increases N6-methyladenosine (m6A) levels and targets the ALKBH5-AXL signaling axis. DDO-02267 can serve as a probe for investigating the biological function of mRNA demethylase.
    DDO-02267
  • HY-117275R
    Meclofenamic acid (Standard)
    		Inhibitor
    Meclofenamic acid (Standard) is the analytical standard of Meclofenamic acid. This product is intended for research and analytical applications. Meclofenamic acid (Meclofenamate) is a non-steroidal anti-inflammatory agent. Meclofenamic acid is a highly selective FTO (fat mass and obesity-associated) enzyme inhibitor. Meclofenamic acid competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid is a non-selective gap-junction blocker. Meclofenamic acid inhibits hKv2.1 and hKv1.1, with IC50 values of 56.0 and 155.9 μM, respectively.
    Meclofenamic acid (Standard)
  • HY-B1320R
    Meclofenamic acid (sodium) (Standard)
    		Inhibitor
    Meclofenamic acid (sodium) (Standard) is the analytical standard of Meclofenamic acid (sodium). This product is intended for research and analytical applications. Meclofenamic acid (Meclofenamate) sodium is a non-steroidal anti-inflammatory agent (NSAID). Meclofenamic acid sodium is a non-selective gap-junction blocker and a highly selective inhibitor of fat - and obesity-related enzyme (FTO). Meclofenamic acid sodium has anti-inflammatory and antitumor activities.
    Meclofenamic acid (sodium) (Standard)
  • HY-131871
    Ethyl LipotF
    		Inhibitor
    Ethyl LipotF is a selective FTO inhibitor that significant increases modified N6-methyladenosine (m6A) levels in HeLa cells in a concentration-dependent manner.
    Ethyl LipotF
Cat. No. Product Name / Synonyms Application Reactivity